Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats

Mediators of Inflammation

Volumn 2005, Issue 2, 2005, Pages 101-111

  Aller, Maria Angeles ^a   Vara, Elena ^a   Garcia, Cruz ^a   Palma, Maria Dolores ^a   Arias, Jorge L ^b   Nava, Maria Paz ^a   Arias, Jaime ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CARBON MONOXIDE; INTERLEUKIN 10; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC HETEROGENEITY; HEPATOMEGALY; ILEUM; IMMUNOCHEMISTRY; IMMUNOPATHOGENESIS; INFLAMMATION; LIVER; LIVER WEIGHT; MALE; MESENTERIC BLOOD VESSEL OCCLUSION; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RAT; SMALL INTESTINE; SPECTROPHOTOMETRY; SPLEEN WEIGHT; TISSUE DISTRIBUTION; VEIN LIGATION;

ANIMALS; BODY WEIGHT; CARBON MONOXIDE; COLLATERAL CIRCULATION; HYPERTENSION, PORTAL; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-10; INTESTINES; LIVER; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS NORVEGICUS;

EID: 25644449477     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1155/MI.2005.101     Document Type: Article

References (64)

1. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am. 1992;21(1):1-14.
2. MacMathuna P, Vlavianos P, Westaby D, Williams R. Pathophysiology of portal hypertension. Dig Dis. 1992;10(suppl 1):3-15.
3. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32(suppl 1):141-156.
4. Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. 2002;18(3):351-359.
5. Lebrec D. Pharmacological treatment of portal hypertension: present and future. J Hepatol. 1998;28(5):896-907.
6. Bosch J, Abraldes JG, Groszmann RJ. Current management of portal hypertension. J Hepatol. 2003;38(suppl 1):S54-S68.
7. Iannitti DA, Henderson JM. Surgery in portal hypertension. Bailliere Clin Gastr. 1997;11(2):351-364.
8. Myking AO, Halvorsen JF. A method for graded portal vein stenosis in rats: survival related to degree of stenosis. Eur Surg Res. 1973;5(6):454-457.
9. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol. 1981;240(5):G371-G375.
10. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol. 1985;248(pt 1):G618-G625.
11. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 1983;244(1):G52-G57.
12. Lin HC, Yang MC, Hou MC, et al. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology. 1996;23(3):537-543.
13. Aller Reyero MA, Diéguez Fernández B, Nava Hidalgo MP, et al. Tipos evolutivos de hipertension portal prehepatica en la rata. An Med Interna. 2002;19(7):341-351.
14. Diez-Arias JA, Aller MA, Palma MD, et al. Increased duodenal mucosa infiltration by mast cell in rats with portal hypertension. Dig Surg. 2001;18(1):34-40.
15. Monterde G, Rodriguez-Fabian G, Vara E, et al. Increased plasma levels of corticosterone and prolactin and decreased T3 and T4 levels in short-term prehepatic portal hypertension in rats. Dig Dis Sci. 2000;45(9):1865-1871.
16. Castaneda B, Dubernardi-Venon W, Bandi JC, et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology. 2000;31(3):581-586.
17. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology. 1986;90(pt 1):1232-1240.
18. Dieguez B, Aller MA, Nava MP, et al. Chronic portal hypertension in the rat by triple-portal stenosing ligation. J Inves Surg. 2002;15(6):329-336.
19. Mester M, Carter EA, Tompkins RG, et al. Thermal injury induces very early production of interleukin-1 alpha in the rat by mechanisms other than endotoxemia. Surgery. 1994;115(5):588-596.
20. Arias-Diaz J, Vara E, Torres-Melero J, Garcia C, Hernandez J, Balibrea JL. Local production of oxygen free radicals and nitric oxide in rat diaphragm during sepsis: effects of pentoxifylline and somatostatin. Eur J Surg. 1997;163(8):619-625.
21. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnock JS, Tannenbaum SR. Analysis of nitrate, nitrite and (15N)nitrate in biological fluids. Anal Biochem. 1982;126(1):131-138.
22. Wolff DG. The formation of carbon monoxide during peroxidation of microsomal lipids. Biochem Biophys Res Commun. 1976;73(4):850-857.
23. Dasarathy S, Mullen KD, Conjeevaram HS, Kaminsky-Russ K, Wills LA, McCullough AJ. Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci. 2002;47(9):1936-1942.
24. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an antiinflammatory drug. Crit Care Med. 2002;30(suppl 1):S58-S63.
25. H2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993;150(2):353-360.
26. Yokoyama Y, Kitchens WC, Toth B, et al. Role of IL-10 in regulating proinflammatory cytokine release by Kupffer cells following trauma-hemorrhage. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G942-G946.
27. Swain MG, Appleyard C, Wallace J, Wong H, Le T. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol Gastrointest Liver Physiol. 1999;276(pt 1):G199-G205.
28. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: A major contributer to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108(3):761-767.
29. Munoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol. 1999;276(pt 1):G687-G693.
30. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004;18(2):353-372.
31. Haddad JJ, Fahlman CS. Redox- and antioxidantmediated regulation of interleukin-10: an antiin-flammatory, antioxidant cytokine? Bioch Bioph Res Commun. 2002;297(2):163-176.
32. Madsen K. Combining T cells and IL-10: a new therapy for Crohn's disease? Gastroenterology. 2002;123(6):2140-2144.
33. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytok Growth Factor Rev. 2002;13(3):223-240.
34. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
35. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83(3):835-870.
36. Lundberg JE, Roth TP, Dunn RM, Doyle JW. Comparison of IL-10 levels in chronic venous insufficiency ulcers and autologous donor tissue. Arch Dermatol Res. 1998;290(12):669-673.
37. Louis H, Le Moine O, Goldman M, Deviere J. Modulation of liver injury by interleukin-10. Acta Gastroenterol Belg. 2003;66(1):7-14.
38. Wang SC, Ohata M, Schrum L, Rippe RA, Tsukamoto H. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem. 1998;273(1):302-308.
39. Leifeld L, Cheng S, Ramakers J, et al. Imbalanced intrahepatic expression of interleukin-12, interferon gamma and interleukin-10 in fulminant hepatitis B. Hepatology. 2002;36(pt 1):1001-1008.
40. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol. 2002;283(2):G256-G265.
41. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 1993;17(6):1081-1085.
42. Alonso MJ, Aller MA, Corcuera MT, et al. Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension. Hepatogastroenterology. In press.
43. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343(20):1467-1476.
44. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev. 2000;174:160-171.
45. Solga SF, Deihl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003;38(5):681-687.
46. Vara E, Arias-Diaz J, Torres-Melero J, Garcia C, Rodriguez JM, Balibrea JL. Effect of different sepsis related cytokines on lipid synthesis by isolated hepatocytes. Hepatology. 1994;20(pt 1):924-931.
47. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nature Med. 2002;8(12):1363-1368.
48. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1 or endotoxin. J Natl Cancer Inst. 1990;82(9):772-776.
49. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35(2):478-491.
50. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337(8744):776-778.
51. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis. 1999;19(4):411-426.
52. Pateron D, Tazi KA, Sogni P, et al. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology. 2000;119(1):196-200.
53. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology. 1998;28(6):1467-73.
54. Murray BM, Paller MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action. Circ Res. 1985;57(3):424-431.
55. Michielsen PP, Boeckxstaens GE, Sys SU, Hernan AG, Pelckmans PA. The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated rats. J Hepatol. 1995;23(3):341-347.
56. Ai JH, Yang Z, Qiu FZ, Zhu T. Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats. World J Gastroenterol. 2003;9(11):2544-2547.
57. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther. 2001;89(3):273-93.
58. Otterbein LE, Choi AMK. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol. 2000;279(6):L1029-L1037.
59. Otterbein LE, Bach EH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated proteinkinase pathway. Nature Med. 2000;6(4):422-428.
60. Fernandez M, Lambrecht RW, Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J Hepatol. 2001;34(6):812-817.
61. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517-554.
62. Suematsu M, Kashiwag S, Sano T, Goda N, Shinoda Y, Ishimura Y. Carbon monoxide as an endogenous modulator of hepatic vascular perfusion. Biochem Biophys Res Commun. 1994;205(2):1333-1337.
63. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: A novel target for the modulation of the inflammatory response. Nature Med. 1996;2(1):87-90.
64. Ponce Gonzalez JF, Dominguez R, Adame Lanuza E, Martin Zurita I, Morales Mendez S. Portal hypertensive colopathy: histologic appearance of the colonic mucosa. Hepatogastroenterology. 1998;45(19):40-43.